Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement

Am J Respir Crit Care Med. 2018 Jun 1;197(11):1483-1486. doi: 10.1164/rccm.201710-2046LE.

Authors

Sonya L Heltshe^{1

2}, Steven M Rowe³, Michelle Skalland², Arthur Baines², Manu Jain⁴; GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network

Affiliations

¹ 1 University of Washington School of Medicine Seattle, Washington.
² 2 CFF Therapeutics Development Network Coordinating Center Seattle, Washington.
³ 3 University of Alabama at Birmingham Birmingham, Alabama and.
⁴ 4 Northwestern University Feinberg School of Medicine Chicago, Illinois.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Aminophenols / therapeutic use*
Child
Chloride Channel Agonists / therapeutic use*
Cystic Fibrosis / drug therapy*
Cystic Fibrosis Transmembrane Conductance Regulator / therapeutic use*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Quinolones / therapeutic use*
Time Factors
Treatment Outcome
Young Adult

Substances

Aminophenols
Chloride Channel Agonists
Quinolones
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor

Grants and funding